SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to discussions around a potential short squeeze and unusual options activity, indicating bullish sentiment. Community members are debating the company's valuation and future prospects in the quantum computing sector, while also referencing collaborations with companies like NVIDIA. Concerns around cash burn and potential dilution are being weighed against the potential for significant growth and government contracts in the burgeoning quantum computing industry.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending following news of a strategic partnership with Perplexity, an AI search company, leading to speculation about further integration of AI on the platform. The community is also focused on the high short interest in RUM and its connection to figures close to Donald Trump. Additionally, the potential acquisition of Northern Data is generating buzz around Rumble's cloud capabilities and partnership with Tether.

Aventus Network

Aventus Network ($AVT) is trending as traders discuss its low market cap, real-world partnerships with Vodafone and Heathrow, and integration with Polkadot; some community members believe $AVT is undervalued and poised for a breakout. Bullish sentiment surrounds the token, with traders closely monitoring volume as a key indicator, while also pointing to the potential of its appchain model. Some are speculating about a potential pump with a government shutdown and are hoping for new all time highs soon.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as investors discuss its price momentum and potential near-term resistance levels, with some eyeing a possible run toward $200. Community members are also weighing in on factors like AI infrastructure deals and potential government shutdowns, considering their impact on the broader market. Additionally, there's chatter around its partnerships with other companies.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending due to its pivot towards quantum computing for cryptocurrency applications, generating excitement around energy-efficient blockchain infrastructure. The community is discussing the potential of LightSolver's laser-based processing units and comparing QCLS to other quantum and crypto-related stocks. Traders are monitoring the stock's threshold list status and anticipating news regarding partnerships and potential contract announcements.

A multi-agent AI platform dissecting human nature’s first principles through iterative survival challenges and data-driven insights. Core dev has access to one of the founding partners of Two Sigma Ventures - the VC company of one of the biggest hedge funds in the world. Plans to raise seed round and scale after building organic foundation. Project devs are from academia space and are trying to bridge the gap between crypto and academia.

CortexZero

CortexZero is trending amid community excitement, with many highlighting the potential for a significant breakout. Discussions are centered around its strong liquidity and the ease of access through Phantom Wallet. The token is gaining traction as a possible next mover within the Solana ecosystem.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid a flurry of activity in the quantum computing sector, including major acquisitions and significant funding rounds for competitors. Community members are actively discussing the potential impact of these developments on QBTS, along with its existing partnerships and recent successes in applying quantum computing to real-world problems. Bullish sentiment is fueled by the belief that QBTS is undervalued compared to peers and poised for significant growth as quantum technology gains wider adoption.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the community rallies around the idea that everyone in crypto is Satoshi Nakamoto, celebrating the ethos of the industry's anonymous creator. Bullish sentiment is fueled by the token's strong community, its forever narrative, and the belief that it represents a second chance to get in early on crypto. Some users suggest that it has strong meme potential, like a version of $BTC.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors discuss its technical setup and potential for a rally, fueled by a recent outperformance and upcoming earnings with projected EPS growth; community talking points include the increasing short positions and the possibility of a short squeeze should a major deal, like a CiC partnership, materialize.  Also, with Sanofi now responsible for commercialization, investors are closely watching uptake and marketing efforts for Nuvaxovid, especially compared to mRNA options.

Chevron Corp. engages in the provision of administrative, financial management, and technology support for energy and chemical operations. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

CVX is trending due to geopolitical tensions in the Middle East and potential supply disruptions, driving discussions around oil prices and strategic positioning. Community members are actively monitoring the situation, with some highlighting unusual options activity and potential breakout opportunities.  Furthermore, Chevron's strategic shift into lithium production and its cost-cutting measures through global restructuring are contributing to the ongoing conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cyclacel Pharmaceuticals, Inc. (CYCC) has been in a downward spiral in 2025, with its stock plunging over 94% year-to-date and more than 76% even after it regained Nasdaq compliance earlier this month.The clinical-stage biotech firm, based in Berkeley Heights, New Jersey, focuses on cancer treatments targeting cell cycle, transcriptional regulation, epigenetics, and mitosis. However, its lead candidates—fadraciclib (a CDK2/9 inhibitor) and plogosertib (a PLK1 inhibitor)—have failed to inspire investor confidence.The trouble began in October 2024, when initial Phase 2 data from a trial of fadraciclib in solid tumors showed only two patients with stable disease among six efficacy-evaluable participants.Research firm Roth MKM called the results “not encouraging,” especially given the patients' favorable genetics, adding that Cyclacel required three or more patient responses to justify continued development.That triggered a sharp fall in <a href="https://stocktwits.com/symbol/CYCC">Cyclacel shares</a>. Struggling to stay afloat, the company then turned to investor David Lazar in January for a $3.1 million funding deal, which included leadership shuffling. Lazar was named interim CEO, replacing longtime chief Spiro Rombotis, and several board members stepped down.In March, Cyclacel raised another $1 million through a private placement of convertible preferred stock.&nbsp;Two months later, Cyclacel pivoted sharply, announcing plans to acquire Fitters Sdn. Bhd., a Malaysian firm focused on fire safety and waste-to-resource solutions. The deal, structured as a share exchange with FITTERS Diversified Bhd., will give the parent company nearly 20% of Cyclacel’s stock. Cyclacel shareholders will retain 80%, and the company said it would rebrand as Bio Green Med Solution, Inc., with a new ticker on the Nasdaq.The merger still requires shareholder approval and must close by Aug. 31.Retail sentiment for CYCC has turned increasingly ‘bearish’ over this period, accompanied by a fourfold jump in message volume over the past month.The company’s rebranding and Nasdaq compliance milestone have failed to stem the stock’s decline, indicating investor skepticism about the firm’s future direction.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Cyclacel Stock Tumbles Over 76% Since Regaining Nasdaq Compliance: What’s Ailing the Nanocap Biopharma Firm?

The company’s rebranding and leadership shuffle have failed to stem the stock’s decline, indicating investor skepticism about its future direction.

Equity

Sangamo Therapeutics, Inc. ($SGMO)Sangamo shares spiked over 30% by the mid-session with sentiment on Stocktwits continuing to remain ‘extremely bullish’ for a second day in running. This marks a turnaround from a week ago when the sentiment score was 35/100.&nbsp;As of 3:05 pm ET, pn Stocktwits the sentiment score was at 97/100. Message volume has improved from ‘normal’ a month ago to ‘extremely high’ this week.&nbsp;On Tuesday, Sangamo announced its successful interaction with the U.S. FDA that provided a clear regulatory pathway to the accelerated approval for ST-920, a wholly-owned gene therapy to treat Fabry disease.&nbsp;The drug regulator agreed in the interaction that the data from the ongoing Phase 1/2 STARR study&nbsp;can serve as the primary basis for approval under the Accelerated Approval Program.&nbsp;“I strongly believe in the potential for ST-920 to alleviate many manifestations of Fabry disease and am delighted to have a clear regulatory pathway that could bring this treatment to patients significantly sooner than originally anticipated,” said Sandy Macrae, CEO of Sangamo.<figure class="image"><a href="https://stocktwits.com/symbol/SGMO"><img style="aspect-ratio:643/147;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/sgmo_sentiment_8fa3195ce2.png" alt="sgmo sentiment.png" width="643" height="147"></a><figcaption>&nbsp;SGMO sentiment and message volume October 22, 2024, as of 3:05 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>The company said it plans to submit the Biologic License Application in 2025.Cyclacel Pharmaceuticals, Inc. ($CYCC)Nano-cap biotech Cyclacel also saw a surge in retail interest. The&nbsp;sentiment meter on Stocktwits&nbsp;was trending in the ‘extremely bullish’ territory, with a score of 96/100 as of 3:05 pm ET. This marked an improvement from the ‘bullish’ predisposition seen on Monday. Message volume has spiked significantly, with the corresponding score improving from 63/100 on Monday to 93/100.<figure class="image"><a href="https://stocktwits.com/symbol/CYCC"><img style="aspect-ratio:627/138;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/cycc_sentiment_58035ef869.png" alt="cycc-sentiment.png" width="627" height="138"></a><figcaption>CYCC sentiment and message volume October 22, 2024, as of 3:05 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>The extremely positive stance of retail traders came ahead of the oncology-focused company’s presentation of the initial safety and efficacy data from&nbsp;12 patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib as a single agent.&nbsp;The data is due to be presented between 6 am ET and1 pm ET on October 23, 2024 at the AACR-NCI-EORTC 36th Symposium on Molecular Targets and Cancer Therapeutics to be held in Barcelona, Spain.GE Aerospace ($GE)GE Aerospace stock was plunging on Tuesday following the company’s third-quarter results, which showed revenue coming in slightly shy of estimates. The adjusted earnings from continuing operations, however, beat the consensus.Retail investors threw their weight behind the company, with the sentiment score on Stocktwits at 96/100 as of 3:05 pm ET, suggesting ‘extreme bullishness.’ The score is up from 79 a day ago. Message volume has been extremely high, with a score of 96/100, up from 72/100 on Monday.&nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/GE"><img style="aspect-ratio:667/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ge_sentiment_f01d6d0683.png" alt="ge-sentiment.png" width="667" height="137"></a><figcaption>GE sentiment and message volume October 22, 2024, as of 3:05 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>As of 3:05 pm ET, Sangamo was up 35.3% at $1.24, Cyclacel gained 12.55% to $1.49, while GE Aerospace fell 8.84% to $177.05.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/texas-instruments-stock-slips-ahead-of-earnings-retail-sentiment-turns-bullish-amid-rise-in-chatter/cJ2XQFWReS">Texas Instruments Stock Slips Ahead Of Earnings, Retail Sentiment Turns Bullish Amid Rise In Chatter</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon

These 3 stocks are riding on catalysts in Tuesday's session.

3 stocks outperforming the broader market Tuesday

A small-cap biotech and a far smaller nano-cap peer and GE Aerospace were among the stocks retail traders were the most bullish about on Tuesday.


Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Sees Large Decline in Short Interest

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC  Get Free Report) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 26,600 shares, a drop of 35.9...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded to "Hold" at StockNews.com

StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a sell rating to a hold rating in a report issued on Tuesday morning.
A number of other brokerages...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Downgraded by StockNews.com

StockNews.com cut shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a hold rating to a sell rating in a research report report published on Monday morning. Other analysts have...

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation Oral Plogosertib Preclinical Data Support Precision...

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Raised to "Hold" at StockNews.com

StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a sell rating to a hold rating in a research note released on Thursday morning. Several other...

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphomaBERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel...

Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on January 5, 1996 and is headquartered in Berkeley Heights, NJ.

Bio Green Med Solution Inc.

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$4.54
Prev Close	$4.93
Open	$4.81
Dividend Yield	0.00%
50-Day Moving Average	$7.99
Beta	0.29
Avg. Volume	87,361.90
PE Ratio	-0.02

52-Week High	$597.60
52-Week Low	$3.08
Market Capitalization	$11.04M
EPS (Annual)	-$502.46
Price to Book	2.15
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

CYCC
Cyclacel Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CYCC News

CYCC Cyclacel Pharmaceuticals Inc